Our ENHANZE™ Technology is a proprietary delivery platform using our first approved enzyme, recombinant human hyaluronidase – rHuPH20. This enzyme temporarily degrades hyaluronan, a structural component of the subcutaneous space that is just beneath the outside surface of the human skin. This temporary degradation creates an opportunistic window for the improved subcutaneous delivery of injectable biologics such as monoclonal antibodies and other large therapeutic molecules, as well as small molecules and fluids. With the hyaluronan temporarily degraded, molecules as large as 200 nanometers may pass freely through the subcutaneous space.
The hyaluronan reconstitutes its normal density within several days and, therefore, any effect of the rHuPH20 on the architecture of the subcutaneous space is temporary. By using Halozyme’s rHuPH20 enzyme, many therapeutics that could normally only be injected intravenously (IV) can now be administered subcutaneously (SC). This change in the route of delivery to SC from IV can often improve patient convenience, enhance used pharmacokinetics, boost efficacy, extend the product lifecycle and reduce cost.
We are seeking additional partnerships with biopharmaceutical companies that market drugs requiring or benefiting from injection via the subcutaneous route of administration. Halozyme currently has four ENHANZE™ Technology partnerships, including one with Hoffman-La Roche to apply the technology to up to eight targets including Hoffman-La Roche’s biological therapeutics Herceptin® and MABTHERA® (both of which are in phase 3 for the development of SC formulations of their products using rHuPH20). Halozyme has four additional partnerships with Baxter Healthcare for immunoglobulin, Pfizer, ViroPharma Incorporated for Cinryze® and Intrexon for alpha-1 anti-trypsin.